According to the National Institutes of Health, approximately 500,000 people in the U.S. have been diagnosed with Parkinson’s disease (PD), and that number is expected to double by 2040.
To date, lecanemab is the first traditional approval of a treatment for Alzheimer’s disease. Lecanemab holds promise for patients in early stages of the disease.